Project Grant HT94252310706

Federal Grant Award Summary The National Cancer Institute awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) a $3.48 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. This project systematically identifies genomic heterogeneity and relapse predictors in pediatric and adolescent/young adult patients with Philadelphia chromosome-positive (PH+) and ABL-class PH-like acute...

Grant Award Summary Seattle Children's Research Institute received a $434,361 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2025 through August 31, 2027. The award supports the development of a multispecific T cell engaging (MTE) therapy targeting mixed-phenotype acute leukemia (MPAL), a high-risk leukemia subtype that presents with both myeloid and lymphoid surface antigens. The research aims to...

Grant Award Summary Cincinnati Children's Hospital Medical Center received a $530,106 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded September 11, 2025, with completion by August 31, 2030. The research project targets polyamine metabolism in leukemia stem cells (LSCs) to develop therapeutic interventions for acute myeloid leukemia (AML). The project delivers fundamental research investigating the mechanistic role of...

The Department of Defense's Defense Health Agency awarded a $3,188,604 Project Grant titled "USE OF HIGH-THROUGHPUT SEQUENCING OF THE IMMUNOGLOBULIN LOCI FOR REFINED RISK STRATIFICATION IN PEDIATRIC B-ALL" to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. This grant, funded through the Military Medical Research and Development (CFDA 12.420) program, supports biomedical research related to military medicine, with a focus on cancer, neurological...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant of $274,829 awarded to Rosebud Biosciences Inc. on August 15, 2023 aims to enable the development of new therapies for rare diseases in children. The project objectives are to: (1) Automate the derivation of heart, liver, and brain organoids from human stem cells, and (2) Develop automated machine learning models to detect disease phenotypes in these organoids derived from patients with...

Federal Project Grant Award Summary The National Cancer Institute (NCI), under its Cancer Treatment Research program (CFDA 93.395), awarded The Children's Hospital of Philadelphia (CHOP) a Project Grant of $457,683 (awarded April 1, 2026, with completion by March 31, 2028) to develop and optimize macromolecular prodrug-based drug delivery systems targeting high-risk neuroblastoma. This research addresses a critical clinical need, as conventional multimodality treatment fails in over 50% of...

This Project Grant award of $275,956.00 from the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program supports the development of an engineered cyber-physical system that combines advanced biological models with state-of-the-art artificial intelligence methods for predictive, automated screening of anti-cancer drugs and optimizing their dosing. The goal is to realize a precision medicine paradigm that can improve health outcomes and reduce treatment...

Sanicka, Inc. was awarded a $793,816 Project Grant from the National Cancer Institute, a component of the Department of Health and Human Services, to develop precision medicine tools for optimizing personalized treatment of patients with acute myeloid leukemia. Under the grant, Sanicka will launch a clinical decision support service called PCITTM Simulator to assist oncologists in simulating disease response and progression for AML patients receiving various chemotherapy, small molecule...

Federal Project Grant Award Summary Boston Children's Hospital received a $178,000 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on June 15, 2025, with completion scheduled for June 14, 2026. The grant supports the development of a bone marrow organoid system to study RUNX1-Familial Platelet Disorder with Associated Myeloid Malignancy (RUNX1-FPD/MM), a rare genetic disorder characterized by germline heterozygous loss-of-function...

This Project Grant award of $434,993 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Children's Hospital Los Angeles. The funding supports research using high-throughput sequencing of the immunoglobulin loci to develop refined risk stratification methods for pediatric B-cell acute lymphoblastic leukemia (B-ALL). The project aims to advance understanding and treatment of this pediatric cancer, with an expected completion...